Cerebral administration of botulinum neurotoxin A (BoNT-A) has been shown to improve disease-specific motor behavior in a rat model of Parkinson disease (PD). Since the dopaminergic system of the basal ganglia fundamentally contributes to motor function, we investigated the impact of BoNT-A on striatal dopamine receptor expression using in vitro and in vivo imaging techniques (positron emission tomography and quantitative autoradiography, respectively). Seventeen male Wistar rats were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and assigned to two treatment groups 7 weeks later: 10 rats were treated ipsilaterally with an intrastriatal injection of 1 ng BoNT-A, while the others received vehicle (n 5 7). All animals were tested for asymmetric motor behavior (apomorphine-induced rotations and forelimb usage) and 
the case of dopamine depletion as observed in PD, reduced cholinergic autoreceptor function contributes to the abundance in ACh (Ding et al., 2006) . Therefore, the increased activation of metabotropic acetylcholine receptors (AChRs) (accompanied by elevated GABAergic and changed glutamatergic receptor activation) alters the signal transduction of MSNs as the main striatal output, which is already less modulated by dopamine. Besides strategies to compensate dopamine deficits, attempts have been made to restore the transmitter balance-for instance, by antagonizing ACh. As an example, it was recently shown that the ablation of ChIs, the main source of striatal ACh (Oldenburg & Ding, 2011) , diminished the risk of induced dyskinesia in L-DOPA-treated hemiparkinsonian mice (Won, Ding, Singh, & Kang, 2014) .
A promising strategy to functionally antagonize striatal cholinergic neurotransmission is local application of botulinum neurotoxin A (BoNT-A), which blocks the release from presynaptic terminals via degradation of the synaptosomal-associated proteins of 25 kDa (Dong et al., 2006; Verderio et al., 2006) . BoNT-A is already in use, particularly in symptomatic therapies of drooling in PD (Egevad, Petkova, & Vilholm, 2014) and in disorders of cholinergic hyperactivity (e.g., dystonia, hyperhidrosis, strabismus, blepharospasm) (Lim & Seet, 2010) .
We have previously investigated a potential therapeutic application of BoNT-A in the 6-hydroxydopamine (6-OHDA) model of PD (Wree et al., 2011) . In this model, unilateral injection of 6-OHDA into the medial forebrain bundle (MFB) leads to rapid degeneration of nigrostriatal neurons (Meredith, Sonsalla, & Chesselet, 2008) , asymmetry in forelimb use (Schallert, Fleming, Leasure, Tillerson, & Bland, 2000) , and drug-induced rotations (Ungerstedt & Arbuthnott, 1970) .
On the molecular level, the loss of nigrostriatal dopamine input causes an imbalance of dopaminergic and cholinergic neurotransmission in the caudate-putamen (CPu). The degeneration of nigrostriatal terminals is also reflected in reduced concentrations of proteins associated with dopamine production and transport (tyrosine hydroxylase and dopamine transporters [DATs] ; Sun et al., 2011) , whereas the longlasting impact of 6-OHDA on proteins related to ACh is not yet clear.
For instance, while Ma et al. (2014) reported a decrease in striatal choline acetyltransferase concentration following 6-OHDA infusions, no changes could be observed by Pezzi, Checa, & Alberch (2005) . We used the 6-OHDA model to test the efficacy of a single intrastriatal administration of BoNT-A. We found significant improvements in motor impairment for up to 6 months after BoNT-A application (Wree et al., 2011) . Histologically, a remarkable number of varicosities were observed at neuronal processes, while the overall quantity of striatal neurons, ChIs, and tyrosine hydroxylase levels remained unchanged (Itakura et al., 2014; Mehlan et al., 2016; Wree et al., 2011) . The number of varicosities declined over time, while remaining varicosities exhibited permanently elevated volumes (Mehlan et al., 2016) . There were no changes in cognitive abilities or in striatal volume at the BoNT-A injection site Holzmann et al., 2012) .
The present study focuses on the molecular changes that underlie the observed improved motor behavior. Downregulation of pathologically increased dopamine D 2 receptor (D 2 R) concentrations is often considered a hint for a promising treatment strategy. We hypothesize that the positive impact of BoNT-A on motor impairments in the unilateral 6-OHDA rat model will be mirrored by more balanced dopamine receptor concentrations (especially for D 2 R) in the CPu, since motor actions are regulated by basal ganglia circuits in which striatal output function is strongly modulated by dopamine. Moreover, we assume that the long-lasting impact on behavior improvement will also be accompanied similarly over time by changes in dopamine receptor concentrations. We designed a longitudinal behavioral and imaging study to investigate components of the dopaminergic system. 6-OHDA rats were treated either with BoNT-A or vehicle and subsequently examined with regard to apomorphine-induced rotation behavior, forelimb use, and dopamine D 1 receptor (D 1 R), D 2 R, and DAT availability with longitudinal positron emission tomography (PET) and quantitative in vitro autoradiography.
| M A TE RI A L S A ND M E THOD S

| Animals
Seventeen adult male Wistar rats (Charles River WIGA, Germany; RRID: RGD_737929) with an age of around 2 months were housed under standard conditions (22 8C 6 2 8C; 12-hr light/dark cycle) with free access to food and water. The animals were randomly assigned to two treatment groups (Figure 1 ):
1. Sham treatment (n 5 7): All animals underwent unilateral lesioning, intrastriatal vehicle administration, behavioral testing, and in vitro examinations (histology and autoradiography). A subset of 5 rats were additionally studied by repeated PET.
2. BoNT-A treatment (n 5 10): All animals underwent unilateral lesioning, intrastriatal BoNT-A administration, behavioral testing, and in vitro examinations (histology and autoradiography). A subset of 5 rats were additionally studied by repeated PET. 
| Unilateral lesioning and treatment
To produce unilateral degeneration of dopaminergic neurons and hemiparkinsonian symptoms, rats weighing 280 6 12 g (n 5 16; one animal's record was lost) were lesioned by injection of 6-OHDA (Sigma-Aldrich, Taufkirchen, Germany; product number H4381) into the right MFB; after intraperitoneal injection of ketamine (50 mg/kg body weight) and xylazine (4 mg/kg body weight) for anesthesia, 4 ll of 6-OHDA (24 lg) dissolved in 0.1 M citrate buffer was delivered over 4 min via a 26-gauge 5-ll Hamilton syringe with the following coordinates referenced from bregma: anteriorposterior 5 22.3 mm, lateral 5 21.5 mm, and ventral 5 29.0 mm (Paxinos & Watson, 2007) .
Seven weeks later, rats (356 6 30 g) received either 1 ng BoNT-A (n 5 10) or vehicle (n 5 7) into the right CPu; after ketaminexylazine anesthesia, rats were treated with two individual injections of 1-ml volume containing either BoNT-A (List, USA, purchased via Quadratech, UK) or 0.1% bovine serum albumin in phosphatebuffered saline ("vehicle"). Each intrastriatal injection was delivered over 4 min and according to the following coordinates (with reference to bregma): anterior 5 1.3/20.4 mm, lateral 5 22.6/23.6 mm, and ventral 5 25.5 mm (Paxinos & Watson, 2007) .
| Behavioral testing
After successful unilateral 6-OHDA-induced dopamine depletion, animals tend to turn contralaterally to the lesioned side after dopaminergic stimulation (Ungerstedt & Arbuthnott, 1970) . Here, 2 weeks before treatment (thus, 5 weeks after 6-OHDA lesioning) and 2 weeks after treatment, all animals were tested on rotational behavior (net contraversive turns per minute) after subcutaneous injection of 0.25 mg/kg body weight apomorphine (Teclapharm, L€ uneburg, Germany). Rotations were measured over 40 min, using a self-constructed automated rotometry device (modified according to Ungerstedt & Arbuthnott, 1970) . Rotations were only analyzed in case of complete 360 8 turns in the left or right direction. All rats were also tested for non-druginduced forelimb use in the same period (2 weeks before and after treatment) by applying the cylinder test (Schallert et al., 2000) Alternating the groups for being injected first, time of injection (T i ) did not differ between sham-and BoNT-A-treated animals and took place at 11:28 a.m. 6 0:22 (10 rats; 3 time points per rat). [ 11 C]raclopride was prepared as described previously (Schott et al., 2008 ) with a radiochemical purity > 95% and a mean specific activity (SA) 5 73 6 34 GBq/mmol (n 5 15) at the end of synthesis. SA did not differ between groups, but was higher at the second scan session (59.85 6 5.40 GBq/ mmol [55.68, 64.03] vs. 30.12 6 20.43 GBq/mmol [14.37, 45 .88] at the first session and 27.02 6 6.95 GBq/mmol [21.66, 32 .38] at the last session with F 1.15,9.17 5 14.79; n 5 10 per session; p 5 .003 and repeated FIG URE 1 Study design. Male Wistar rats with unilateral 6-OHDA injection into the right MFB received either 1 ng BoNT-A (n 5 10) or vehicle (n 5 7) into the ipsilateral CPu. Two weeks before and after treatment, animals were tested for motor performance by determining apomorphine (APO)-induced rotational behavior and forelimb use. D 2 R availability was longitudinally quantified with PET and [
11 C]raclopride at 1.5, 3, and 5 months after treatment.
Finally, D 1 R, D 2 R, and DAT autoradiography and histological stainings for cell bodies and myelin were performed in vitro subsequent to the last PET scan.
contrasts F 1,8 16.10; p .004). More PET parameters are listed in Table 1 .
PET data were acquired in list mode for 70 min, normalized and 
| Tissue preparation for in vitro studies
All rats were sacrificed by decapitation under isoflurane anesthesia 5 months after treatment (rats which received a PET scan were decapitated immediately after the last scan). Each brain was dissected quickly Mixed 1-way RM-ANOVA showed no significant differences for each parameter between sham-and BoNT-A-treated animals at any of the 3 PET scans. Parameters are given as mean (SD), n 5 5 per treatment group. Activity, dose, and mass are adjusted to time of injection (T i ); duration of anesthesia is displayed only as time elapsed until start of emission, and receptor occupancy is calculated based on mass at T i and ED 50 5 17.1 nmol/kg with receptor occupancy 5 activity/(weight * specific activity * ED 50 ) 1 1 (Hume, Gunn, & Jones, 1998 
| Histology
For optimal ROI definition, histology was performed on corresponding brain sections, which were fixated in neutral-buffered formalin-solution (30 min), washed in deionized water (2 3 5 min) and stained with cresyl violet (30 min) for Nissl substance. Additionally, cell bodies or myelin were stained in alternating formalin-fixated sections following the protocols of Merker and Gallyas, respectively (Gallyas, 1979; Merker, 1983) . In brief, after several pre-treatment and washing steps, slides were transferred to developer solutions containing silver nitrate (70 min for cell body or 30 min for myelin staining, respectively). Sections were washed, fixated in a T-max fixation solution (Kodak, Germany; product number 5089198) and washed again. All sections were dehydrated in ascending solutions of propanol (70%-100%), cleared in XEM-200 (2 3 10 min; Vogel, Germany, purchased via Diatec, Bamberg, Germany; product number 1-019614), mounted in DPX (SigmaAldrich, Taufkirchen, Germany; product number 44581) and dried until digital processing using Axiovision (Zeiss, G€ ottingen, Germany, RRID: SCR_002677).
Pretreatment and washing steps in silver-based cell body and myelin stainings were as follows:
Pretreatment: overnight incubation in formic acid and hydrogen peroxide (cell bodies) or in pyridine and acetic anhydride (Sigma-Aldrich;
Taufkirchen, Germany; product number 822278) (myelin), respectively. 
| R ESU L TS
Effects of intrastriatal BoNT-A treatment on 6-OHDA rats were investigated longitudinally with behavioral testing and PET, and in vitro with autoradiography and histological techniques. The time course of experimental procedures is depicted in Figure 1 .
| Unilateral 6-OHDA lesion
All investigated animals (n 5 17) underwent unilateral dopamine depletion by application of 4 ml 6-OHDA into the right MFB. Individual lesion effects were verified both in vivo by assessing apomorphine-induced
rotations and spontaneous forelimb-usage 5 weeks after lesioning and in vitro by DAT autoradiography. It is to note that tyrosine hydroxylase quantification was not feasible in non-fixated samples and thus outcome of behavioral tests and quantification of striatal DAT were used to determine nigrostriatal degeneration (Heuer, Smith, Lelos, Lane, & Dunnet, 2012; Liu, Zhang, Gong, Liang, & Wang, 2014; MolinetDronda et al., 2015) .
Behavioral testing showed typical asymmetrical rotational movements (8 6 2.72 contraversive turns/min after apomorphine stimulation; n 5 17) and forelimb usage (L/R ratio of 0.36 6 0.36; n 5 17). There were no behavioral differences between animals assigned to treatment and sham groups. After completion of the in vivo investigations, all brains underwent in vitro DAT autoradiography in order to quantify the lesion effect and the impact of BoNT-A on presynaptic DAT. All lesioned brains displayed a strong ipsilateral reduction of DAT (90.01% 6 8.89%; n 5 17) without any difference between BoNT-A and sham-treated animals. Furthermore, there was a massive reduction of silver-stained Nisslpositive cell bodies in the ipsilateral substantia nigra (Figure 2A-C) .
| BoNT-A treatment
The 6-OHDA lesioned rats were assigned to two groups with either
BoNT-A (n 5 10) or sham (n 5 7) treatment. There were no differences between these groups with regard to 6-OHDA lesion effects and body weight. All animals underwent behavioral testing before and after treatment ( Figure 1 ). Before treatment, 6-OHDA animals showed turns in opposite direction to the lesioned side and prevalent right forelimb usage. There were no differences between the treatment groups. After
BoNT-A treatment, scores for rotational behavior were significantly different with regard to reduced asymmetry (1.32 6 1.05 vs. 6.78 6 3.72 contraversive turns/min, GLM with F 1,14 5 21.21; n 5 7-10; p 5
.0004). In contrast, BoNT-A did not affect forelimb preference, although differences in L/R usage tend to be diminished (0.62 6 0.37 vs. 0.24 6 0.36) ( Figure 2C ).
FIGU RE 2.
F IGURE 2 Unilateral 6-OHDA lesion. Unilateral 6-OHDA lesioning was proven by asymmetry in striatal DAT concentration, nigral cell body number, and motor behavior. Table 1 ).
There was a constant trend towards higher [ 
| In vitro autoradiography
Striatal D 1 R and D 2 R binding sites were studied with quantitative autoradiography in all animals 5 months after treatment ( Figure 5 and Table 3 ). n 5 7-10; p 5 .006 and t 15 5 3.49; n 5 7-10; p 5 .003, respectively).
For in vitro raclopride (D 2 R) data, there was an excellent correlation to in vivo interhemispheric changes, measured by PET 5 months after treatment (Pearson r 5 0.964, n 5 10, p < .0001).
| D I SCUSSION
In the present study, we explored the longitudinal effects of a BoNT-A application in 6-OHDA lesioned rats on striatal markers of the dopa- A broad range of short-and long-term side effects limits the use of anticholinergic medications in PD (Calabresi et al., 2006; Katzenschlager, Sampaio, Costa, & Lees, 2003; Lim et al., 2014) . BoNT-A injected into the ipsilateral striatum of hemiparkinsonian rats reduces hypercholinism directly at the site of action (Holzmann et al., 2012) and improves motor function for up to 6 months without inflammatory reactions or side effects on cognitive behavior Wree et al., 2011) . To understand the molecular mechanisms underlying these actions of BoNT-A, we investigated postsynaptic dopamine receptors, which are of crucial importance for basal ganglia circuitry and connectivity.
Our findings indicate that BoNT-A affects striatal D 1 and D 2 binding sites similarly, since both were reduced 5 months after intervention.
It is unlikely that this downregulation is caused by neurotoxic effects as numbers of striatal neurons are unchanged up to 12 months after treatment . Moreover, it appears implausible that alleviation in 6-OHDA-induced D 2 R binding is independent of BoNT-A, because interhemispheric differences have been shown to persist at later stages (Blunt, Jenner, & Marsden, 1992; Sun et al., 2011) and were also detected in the sham-treated animals here. Likewise, results from PET investigations on patients with PD and parkinsonian monkeys suggest that the downregulation of pathologically increased D 2 R concentrations is most probably caused by long-term treatment with dopamine agonists rather than by disease progression (Doudet, Jivan, Ruth, & Holden, 2002; Seeman & Niznik, 1990) . In an earlier study it has also been shown that blockade of muscarinic interactions leads to reduced [
11 C]raclopride binding in monkeys (Tsukada, Harada, Nishiyama, Ohba, & Kakiuchi, 2000) ; we therefore assume that BoNT-A treatment normalizes striatal raclopride binding by an inhibition of ACh neurotransmission. Whether this impact of BoNT-A on D 2 R availability is time dependent has yet to be clarified, since the variability in our PET data is comparable to that described in the literature (Lettfuss et al., 2012) , but the lesion-induced differences may be too small to evaluate treatment effects (differences between sham and BoNT-A treatment did not reach significance in the microPET experiments at 1.5 and 3 months). Mixed 2-way RM-ANOVA showed no significant differences between sham-and BoNT-A-treated animals at any of the 3 PET scans. BP ND s are displayed as mean (SD) with n 5 5 per treatment group. SRTM and Logan reference modeling were performed on striatal (referenced to cerebellar) TACs. Modeling was performed from minute 20 onwards and with fixed k 2 0 5 0.24/min in case of Logan-derived BP ND .
Regarding D 1 R and their striatal expression during PD, data are conflicting, showing either no or bidirectional changes in untreated and treated conditions (Blunt et al., 1992; Fornaretto, Caccia, Caron, & Fariello, 1993; Guigoni et al., 2005; Hurley & Jenner, 2006) . Downregulation of D 1 R mRNA and receptor protein by 6-OHDA intervention was small, was only found in animals with medium-sized lesions, and was unaffected by intrastriatal implantation of dopamine cells (Blunt et al., 1992; Da Cunha et al., 2008) . We therefore hypothesize that, in the present study, the reduction in D 1 R concentrations is attributable to BoNT-A instead of 6-OHDA intervention. On the other hand, no change in striatal D 1 R expression was observed in mice lacking the muscarinic M 4 AChR (M 4 mAChR) (Schmidt et al., 2011) Preclinical studies on rodents illustrate that unbalanced limb use and turning behavior are reduced when abating the predominance of ACh by nigrostriatal intervention (Maurice et al., 2015; Won et al., 2014) . Blockade of M 4 mAChR, located on D 1 MSNs (Lim et al., 2014) , alleviates the akinetic dysfunction in a 6-OHDA lesion model (Ztaou et al., 2016) . ACh-induced changes in electrophysiology of D 2 MSNs (Day, Wokosin, Plotkin, Tian, & Surmeier, 2008) provoke PD-like akinesia in mice (Kondabolu et al., 2016; Maurice et al., 2015) . In the present study, we detected dopamine receptor changes after BoNT-A treatment, along with alleviated turning asymmetry described in the literature Wree et al., 2011) . We confirmed that
BoNT-A dosage was insufficient to improve forelimb deficits (Wree et al., 2011) , but individual forelimb akinesia correlated to interhemispheric differences in raclopride binding during the entire time course.
These findings raise the question of whether there is a causal link between ACh levels, behavioral alterations, and changes in dopamine 
